Skip to main content

Table 6 Immune function means (± SD), minima and maxima by dosage level, gender and smoking status.

From: A forced titration study of the antioxidant and immunomodulatory effects of Ambrotose AO supplement

Secondary Outcome Measures    Non Smoker Smoker
    N Mean SD Min Max N Mean SD Min Max
Mature t cell Number Male Baseline 1 5 1.52 0.31 1.10 1.77 3 2.18 0.62 1.74 2.62
   Baseline 2 5 1.56 0.31 1.19 1.99 3 1.75 0.07 1.68 1.82
   Dose 1 5 1.56 0.29 1.23 1.82 3 1.97 0.28 1.69 2.25
   Dose 2 5 1.50 0.40 1.12 1.99 3 1.81 0.16 1.63 1.94
   Dose 4 5 1.56 0.56 1.11 2.31 3 1.93 0.25 1.64 2.12
   Dose 8 5 1.65 0.54 1.21 2.37 3 2.20 0.39 1.84 2.62
  Female Baseline 1 8 1.56 0.46 1.00 2.17 6 2.01 0.68 0.97 2.76
   Baseline 2 8 1.59 0.34 1.09 1.99 6 2.01 0.70 0.95 2.98
   Dose 1 8 1.56 0.29 1.07 1.93 6 1.99 0.74 0.80 2.75
   Dose 2 8 1.68 0.39 0.99 2.12 6 1.99 0.67 0.86 2.76
   Dose 4 8 1.55 0.35 0.95 1.97 6 1.99 0.77 0.89 2.97
   Dose 8 8 1.63 0.46 1.02 2.26 6 1.85 0.74 1.11 2.87
Mature b cell number Male Baseline 1 5 0.24 0.08 0.17 0.36 3 0.50 0.15 0.39 0.60
   Baseline 2 5 0.22 0.06 0.16 0.31 3 0.37 0.16 0.26 0.55
   Dose 1 5 0.25 0.10 0.14 0.36 3 0.39 0.11 0.32 0.52
   Dose 2 5 0.22 0.06 0.14 0.28 3 0.36 0.14 0.27 0.52
   Dose 4 5 0.22 0.06 0.15 0.30 3 0.36 0.15 0.27 0.53
   Dose 8 5 0.22 0.05 0.19 0.30 3 0.42 0.18 0.29 0.63
  Female Baseline 1 8 0.24 0.05 0.17 0.34 6 0.39 0.17 0.23 0.59
   Baseline 2 8 0.24 0.05 0.16 0.29 6 0.32 0.16 0.11 0.53
   Dose 1 8 0.25 0.08 0.15 0.37 6 0.32 0.13 0.14 0.50
   Dose 2 8 0.26 0.08 0.16 0.38 6 0.33 0.14 0.17 0.54
   Dose 4 8 0.24 0.06 0.15 0.34 6 0.35 0.20 0.11 0.60
   Dose 8 8 0.25 0.05 0.18 0.30 6 0.34 0.17 0.12 0.49
Helper t cell number Male Baseline 1 5 0.99 0.30 0.58 1.23 3 1.27 0.18 1.14 1.40
   Baseline 2 5 0.98 0.31 0.69 1.40 3 1.19 0.31 0.88 1.50
   Dose 1 5 1.01 0.31 0.59 1.28 3 1.32 0.23 1.13 1.58
   Dose 2 5 0.99 0.39 0.63 1.43 3 1.21 0.28 0.99 1.53
   Dose 4 5 1.02 0.47 0.58 1.61 3 1.29 0.37 1.06 1.71
   Dose 8 5 1.09 0.52 0.64 1.76 3 1.53 0.53 1.22 2.14
  Female Baseline 1 8 0.96 0.29 0.70 1.46 6 1.24 0.39 0.60 1.61
   Baseline 2 8 1.00 0.22 0.73 1.29 6 1.24 0.38 0.61 1.59
   Dose 1 8 0.97 0.15 0.73 1.20 6 1.24 0.46 0.52 1.83
   Dose 2 8 1.06 0.23 0.66 1.33 6 1.23 0.39 0.56 1.75
   Dose 4 8 0.98 0.21 0.62 1.18 6 1.25 0.49 0.59 2.06
   Dose 8 8 1.02 0.27 0.61 1.29 6 1.10 0.29 0.75 1.44
Suppressant t cell number Male Baseline 1 5 0.47 0.12 0.28 0.59 3 0.77 0.54 0.39 1.15
   Baseline 2 5 0.54 0.19 0.28 0.81 3 0.54 0.25 0.38 0.83
   Dose 1 5 0.51 0.17 0.27 0.75 3 0.61 0.31 0.42 0.96
   Dose 2 5 0.50 0.17 0.31 0.70 3 0.55 0.23 0.37 0.81
   Dose 4 5 0.52 0.19 0.29 0.72 3 0.59 0.26 0.43 0.89
   Dose 8 5 0.53 0.17 0.31 0.66 3 0.63 0.18 0.49 0.84
  Female Baseline 1 8 0.55 0.20 0.30 0.89 6 0.77 0.43 0.36 1.50
   Baseline 2 8 0.53 0.16 0.31 0.80 6 0.74 0.45 0.33 1.62
   Dose 1 8 0.54 0.15 0.34 0.79 6 0.72 0.42 0.27 1.50
   Dose 2 8 0.55 0.19 0.30 0.86 6 0.72 0.42 0.29 1.51
   Dose 4 8 0.53 0.16 0.32 0.81 6 0.73 0.41 0.29 1.45
   Dose 8 8 0.56 0.24 0.31 0.98 6 0.77 0.54 0.33 1.55
Natural killer cell number Male Baseline 1 5 0.20 0.14 0.08 0.44 3 0.36 0.02 0.34 0.37
   Baseline 2 5 0.22 0.16 0.12 0.50 3 0.27 0.04 0.24 0.31
   Dose 1 5 0.19 0.13 0.11 0.41 3 0.29 0.02 0.28 0.32
   Dose 2 5 0.13 0.04 0.09 0.17 3 0.29 0.03 0.26 0.31
   Dose 4 5 0.16 0.06 0.10 0.21 3 0.30 0.03 0.27 0.32
   Dose 8 5 0.17 0.08 0.07 0.24 3 0.34 0.12 0.26 0.48
  Female Baseline 1 8 0.18 0.08 0.10 0.32 6 0.21 0.12 0.12 0.41
   Baseline 2 8 0.18 0.06 0.10 0.28 6 0.25 0.15 0.10 0.50
   Dose 1 8 0.19 0.08 0.10 0.35 6 0.21 0.09 0.12 0.37
   Dose 2 8 0.20 0.07 0.11 0.29 6 0.24 0.12 0.11 0.45
   Dose 4 8 0.17 0.06 0.10 0.26 6 0.25 0.09 0.14 0.37
   Dose 8 8 0.18 0.09 0.09 0.31 6 0.32 0.18 0.14 0.56
Phagocytosis of Granulocytes Male Baseline 1 5 37.1 6.0 31.0 44.4 3 40.6 1.3 39.6 41.5
   Baseline 2 5 47.6 5.1 39.6 53.2 3 40.4 8.4 31.0 47.2
   Dose 1 5 35.4 3.1 33.0 39.8 3 48.0 4.9 42.4 51.6
   Dose 2 5 48.8 14.3 27.5 58.1 3 49.2 15.0 32.8 62.2
   Dose 4 5 40.4 6.3 30.9 44.5 3 38.6 3.0 35.2 40.6
   Dose 8 5 48.6 3.4 44.5 51.5 3 48.1 5.5 43.7 54.2
  Female Baseline 1 8 38.8 10.1 27.6 57.3 6 40.0 8.8 27.1 49.3
   Baseline 2 8 51.4 7.4 37.6 60.7 6 53.8 8.0 46.0 65.2
   Dose 1 8 49.3 13.3 33.3 75.7 6 46.3 9.0 32.9 57.9
   Dose 2 8 46.0 13.9 26.6 64.2 6 51.4 13.8 28.6 65.9
   Dose 4 8 39.5 7.3 34.8 51.7 6 48.5 8.8 36.2 58.6
   Dose 8 8 50.9 8.9 39.5 63.7 6 56.3 6.7 47.0 61.9
Phagocytosis of monocytes Male Baseline 1 5 31.1 4.5 24.9 35.6 3 29.1 3.5 26.6 31.5
   Baseline 2 5 35.5 2.2 33.3 38.9 3 30.4 9.4 23.9 41.2
   Dose 1 5 27.1 3.2 23.5 32.0 3 35.3 3.1 31.9 38.0
   Dose 2 5 38.4 10.8 22.5 45.7 3 35.4 10.1 25.8 46.0
   Dose 4 5 31.8 5.7 25.1 37.6 3 27.4 1.4 25.8 28.3
   Dose 8 5 37.6 1.8 35.8 39.7 3 32.4 5.4 26.5 37.2
  Female Baseline 1 8 34.7 8.4 20.0 47.3 6 32.4 5.1 25.3 39.2
   Baseline 2 8 39.5 7.7 28.9 47.7 6 39.3 5.4 30.3 45.1
   Dose 1 8 35.5 8.1 26.0 49.0 6 34.6 6.5 24.8 42.6
   Dose 2 8 33.1 7.3 22.5 45.3 6 33.8 9.5 21.5 49.8
   Dose 4 8 30.9 4.6 25.0 38.6 6 36.2 7.5 30.5 49.8
   Dose 8 8 32.5 5.5 24.0 39.9 6 34.5 8.8 24.4 44.8
Natural killer cell cytotoxicity Male Baseline 1 5 15.5 6.0 10.6 25.2 3 22.0 0.9 21.3 22.6
   Baseline 2 5 18.7 5.4 11.0 25.4 3 22.8 17.0 10.7 34.8
   Dose 1 5 18.1 6.8 10.4 24.8 3 22.4 4.5 17.6 26.5
   Dose 2 5 13.7 4.8 7.5 19.3 3 21.8 3.9 17.3 24.7
   Dose 4 5 14.1 4.1 8.9 19.0 3 23.5 6.6 17.6 30.6
   Dose 8 5 15.1 2.8 11.3 17.8 3 23.2 6.0 19.6 30.1
  Female Baseline 1 8 14.8 5.9 9.1 24.0 6 15.1 4.5 10.6 21.5
   Baseline 2 8 13.9 5.7 8.7 25.6 6 16.5 6.6 8.6 23.4
   Dose 1 8 15.0 5.3 8.9 24.6 6 16.4 4.9 10.4 23.9
   Dose 2 8 14.1 5.2 8.6 21.6 6 16.6 4.5 10.0 20.8
   Dose 4 8 13.4 4.3 7.6 19.1 6 13.3 5.5 4.1 19.3
   Dose 8 8 12.5 5.0 7.8 19.1 6 15.9 7.5 10.5 26.5
Cox 2 Male Baseline 1 5 78.0 8.9 67.8 89.6 3 83.6 3.9 80.8 86.3
   Baseline 2 5 82.9 2.9 79.7 85.3 3 83.0 2.2 80.6 85.0
   Dose 1 5 82.6 3.1 79.0 86.4 3 85.1 4.1 82.5 89.9
   Dose 2 5 83.2 1.4 82.2 85.3 3 79.6 2.2 78.1 82.1
   Dose 4 5 78.2 5.1 73.8 85.2 3 84.8 5.0 80.9 90.5
   Dose 8 5 79.4 3.6 75.4 83.5 3 85.8 8.5 76.2 92.5
  Female Baseline 1 8 78.9 5.9 71.8 87.9 6 80.2 5.4 76.3 89.4
   Baseline 2 8 81.0 5.5 72.0 88.5 6 79.2 9.1 61.9 85.8
   Dose 1 8 82.6 3.5 75.9 88.0 6 85.9 3.0 82.7 90.3
   Dose 2 8 83.6 3.8 77.3 89.2 6 81.3 4.0 74.8 86.0
   Dose 4 8 81.0 4.3 73.4 85.2 6 83.7 4.8 78.4 92.3
   Dose 8 8 81.3 5.2 76.1 90.1 6 82.7 5.5 76.9 87.6
  1. Baseline 1 and 2 were taken prior to the administration of study preparation.